Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Celularity Inc (CELU) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/25/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Loan Agreement, among Celularity Inc. and the lenders thereto",
"Loan Agreement, among Celularity Inc. and the lenders thereto"
08/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/28/2023 8-K Quarterly results
06/16/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENT OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF"
05/31/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "THE NEXT EVOLUTION IN CELLULAR MEDICINE"
05/19/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...
Docs: "ARTICLE I.",
"FORM OF COMMON STOCK PURCHASE WARRANT Celularity Inc. Warrant Shares: [ ] Issue Date: May 18, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [ ] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May 18, 2023 and on or prior to 5:00 p.m. on May 18, 2028 , but not thereafter, to subscribe for and purchase from Celularity Inc., a Delaware corporation , up to [ ] shares of Class A common stock, par value $0.0001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth i...",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of May 18, 2023, between Celularity Inc., a Delaware corporation , and each of the several Holders signatory hereto. This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date thereof, between the Company and each Purchaser party thereto . The Company and each Holder hereby agree as follows: 1. Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: “Advice” shall have the meaning set forth in Section 6. “Effectiveness Date” means, with ..."
05/16/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "LOAN agreement"
04/27/2023 8-K Quarterly results
03/23/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "ARTICLE I.",
"COMMON STOCK PURCHASE WARRANT Celularity Inc.",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of [•], 2023, between Celularity Inc., a Delaware corporation , and each of the several Holders signatory hereto. This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser party thereto . The Company and each Holder hereby agree as follows: 1. Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: “Advice” shall have the meaning set forth in Section 6. “Effectiveness Date” means, with resp...",
"LOAN agreement",
"CELULARITY INC. By: Name: Title: Address: Celularity Inc. 170 Park Ave Florham Park, New Jersey 07932 9 ACKNOWLEDGED AND AGREED: HOLDER: C.V. STARR &CO., INC. By: ____________________________ Name: Title: Address: C.V. Starr & Co., Inc. 399 Park Avenue, 17th Floor 10022 Attn: Howard Smith Email: [email protected] With a copy to: Starr Insurance Holdings, Inc. 399 Park Avenue, 3rd Floor 10022 Attn: Thomas A. Bryan, Assistant General Counsel Email: [email protected] 10 EXHIBIT A Form of Notice of Exercise To: Celularity Inc. 170 Park Ave Florham Park, New Jersey 07932 By checking the appropriate line, the undersigned , pursuant to the provisions set forth in the Amended and Restated Warrant to Purchase Class A Common Stock, dated March [17], 2023 , hereby elects t..."
03/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "35. The Company repeats and reiterates the allegations set forth above as if fully set forth herein. 36. The Company is authorized to bring this Petition under8 Del. C. §205, which provides that this Court may determine the validity and effectiveness of any corporate act, defective corporate act and any putative stock. 37. The Company consummated the Merger and filed the New Certificate of Incorporation, which effected the Class A Increase Amendment, in the good faith belief that the New Certificate of Incorporation was adopted in compliance with Delaware law. 38. The Company has since treated the New Certificate of Incorporation, as well as the Class A Increase Amendment, as valid and has treated all acts in reliance on the New Certificate of Incorporation as valid. 39. The Company issued..."
03/17/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
01/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CELULARITY COMPLETES STRATEGIC REVIEW OF 2023 INITIATIVES, INCLUDING ANTICIPATED BIOMATERIALS PRODUCTION RAMP-UP AND PIPELINE PRIORITIZATION OF NEXT-GENERATION PRODUCT CANDIDATES"
12/16/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
Docs: "Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction cancer - Appointed Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer and announced the promotion of two senior executives and the formation of a new Executive Committee - Presenting an abstract at the Society for Immunotherapy of Cancer 37th Annual Meeting that supports the scientific rationale of the CYNK-101 - Strengthened balance sheet using a combination of a $150 million at-the-market facility and a $150 million pre-paid advance agreement Florham Park, NJ, – November 10, 2022 – Celularity Inc. , a clinical-stage biotechnology company deve..."
10/06/2022 8-K Quarterly results
09/23/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/15/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Opinion of Goodwin Procter LLP as to the legality of the securities being registered",
"Pre-Paid Advance Agreement, by and between Celularity Inc. and YA II PN, Ltd"
09/08/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "At-the-Market Sales Agreement, by and among the Celularity Inc., BTIG, LLC, Oppenheimer & Co. Inc. and B. Riley Securities, Inc",
"Opinion of Goodwin Procter LLP as to the legality of the securities being registered"
08/09/2022 8-K Quarterly results
Docs: "Celularity Reports Second Quarter 2022 Financial Results and Corporate Update"
07/20/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/14/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
Docs: "Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update"
05/03/2022 8-K Other Events  Interactive Data
03/31/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update"
03/16/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
02/16/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers"
01/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers"
12/28/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML"
12/17/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy